• Perspective: Life sciences in peril—Denver Gazette
• RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations —Janssen Global
• HER2 Biomarker Isn’t Just About Her —Upstage Lung Cancer
• Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions— Journal of Clinical Oncology
• Lung Cancer Considered Podcast featuring Marcia Horn discussing exon 20 issues and the FDA-approved exon 20 drugs—International Association for the Study of Lung Cancer (IASLC)
• The Importance of Molecularly Defined Patient Advocacy Groups —Lighthouse, by Celerity Biosciences
• Three questions to help those with newly diagnosed cancer:—Steve Henderson, Ph.D.'s Post
• Marcia Horn Discusses Advancements in EGFR Exon 20 Insertion+ NSCLC and the Importance of Community—AJMC (American Journal of Managed Care)
• Exon 20 Group Patient Advocate Katina Bland took part in a discussion panel featured in "If You Have Lungs You Can Get Lung Cancer: Part II" by Impact Church of East Point, Georgia. This panel starts at 43:27 into the video.
• Exon 20 Group Patient Advocate Katina Bland was interviewed in a series of videos explaining the patient journey and the importance of Next Generation Sequencing—CURE® Media Group
• Arizona Governor Doug Ducey signs legislation requiring health insurance plans to cover biomarker testing when there’s a clinical need—Office of the Governor of Arizona, news release May 5, 2022
• The Gratitude Symposium—May 2022, Hosted by Quint Studer & The Gratitude Group— A Free month-long symposium to thank healthcare workers. ICAN CEO Marcia K. Horn is part of the lineup!
• Navigating a Lung Cancer Diagnosis: 4 Key Considerations for Patients—Lisa Cruz, Patient Advocacy Lead, Takeda Oncology and Marcia K. Horn, Executive Director, Exon 20 Group at ICAN, International Cancer Advocacy Network. Published in Cure
• Opinion: Congress must turn tide in war on cancer—Sidney M. Rosen, JD, Founding Chairman of ICAN. Published in Scottsdale Progress
• Announcing the Biomarker Collaborative and NeoGenomics Strategic Partnership, benefiting the Exon 20 Group at ICAN and other Rare Mutation Groups—NeoGenomics, Inc.
• New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation: What to Know—American Society of Clinical Oncology
• Structure-based classification predicts drug response in EGFR-mutant NSCLC—Nature
  "One of the most important journal articles written in this field-- Bravo to Jacqulyne Ponville Robichaux, PhD, John Heymach,MD, PhD, and members of the John V. Heymach Laboratory at The University of Texas MD Anderson Cancer Center."—Marcia K. Horn, JD
• FDA Approves Mobocertinib for NSCLC with EGFR Exon 20 Insertion Mutations—Oncology Nursing News
  "As a patient advocate working with EGFR Exon20 insertion+ NSCLC patients and their families every day for nearly five years, I am thrilled to witness continued progress in the fight against this devastating disease and am grateful for the patients, families, healthcare professionals and scientists across the globe who contributed to the approval of this promising targeted therapy." —Marcia Horn, executive director, Exon 20 Group at ICAN, International Cancer Advocacy Network.
• Takeda's EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC —Business Wire
  − Approval based on Phase 1/2 trial results, which demonstrated clinically meaningful responses with a median duration of response (DoR) of approximately 1.5 years
  − Next-generation sequencing (NGS) companion diagnostic test approved simultaneously to support identification of patients with EGFR Exon20 insertion mutations
• Mobocertinib for Patients with EGFR Exon 20 Insertion-Positive Metastatic NSCLC with Disease Progression on Prior EGFR TKI Therapy
  Marcia K. Horn, JD, Executive Director, the Exon 20 Group and CEO, ICAN, International Cancer Advocacy Network—IASLC
  In reference to: OA15.01 "Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy" presented by Dr. Alexander I. Spira | (PDF)
• Phase I studies of DZD9008, an oral selective EGFR/HER2 inhibitor for patients with advanced NSCLC and EGFR Exon20 insertion mutations
  Marcia K. Horn, JD, Executive Director, the Exon 20 Group and CEO, ICAN, International Cancer Advocacy Network—IASLC
  In reference to: OA15.02 "Phase 1 studies of DZD9008, an oral selective EGFR/HER2 inhibitor in advanced NSCLC with EGFR Exon20 insertion mutations," presented by Dr. Pasi Jänne | (PDF)

Adopting Consensus Terms for Testing in Precision Medicine—AASCO Journal of Clinical Oncology

"Despite the well-understood benefits of biomarker and genetic testing in precision medicine, uptake remains low, particularly for patients with low socioeconomic status and minority ethnic backgrounds... A LUNGevity Foundation... assessed and recommended specific terms for communicating with patients on testing for tumor characteristics and germline mutations. Read this article

• Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With EGFR-Mutated NSCLC - Marcia K. Horn, JD | Kevin Liu, PharmD | Susan D. Mathias, MPH | Tracy Li, PhD | Parthiv Mahadevia, MD | Renee F. Pierson, MBA
  Open AccessPublished:June 09, 2021DOI:https://doi.org/10.1016/j.jtocrr.2021.100198

---

ICAN Co-authors Letter on COVID-19 Intellectual Property Waiver

"Waiving intellectual property rights on COVID-19 vaccines initially sounds good, but is a threat to the drug discovery pipeline that cancer patients and all patients depend on."
— Marcia K. Horn, ICAN CEO and Exon 20 Group Executive Director   Read the letter

---

First Exon 20 Drug Approved!

"Congratulations to Janssen Oncology and its principal investigators and study teams as well as to amivantamab patients and their families throughout the Exon 20 Group."
— Marcia K. Horn, ICAN CEO and Exon 20 Group Executive Director   Full article here!

---

Exon 20 Group Members Acknowledged!

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

"The authors wish to thank the patients, families, and caregivers involved in the clinical trial as well as the Exon 20 Group, Marcia Horn, Robert Hanlon, and Kevin Hanlon."
—See article at cell.com/cancer-cell